Cargando…
Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone‐exposed neonates
We aimed to compare the outcomes of pharmacotherapy with either buprenorphine or methadone in infants treated for neonatal abstinence syndrome (NAS) secondary to intrauterine exposure to methadone. This is a multi‐center, retrospective cohort study to assess length of treatment (LOT), hospital lengt...
Autores principales: | Taleghani, Afshin A., Isemann, Barbara T., Rice, Ward R., Ward, Laura P., Wedig, Kathy E., Akinbi, Henry T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975186/ https://www.ncbi.nlm.nih.gov/pubmed/35548374 http://dx.doi.org/10.1002/pne2.12008 |
Ejemplares similares
-
Neonatal Abstinence Syndrome in Infants with Prenatal Exposure to Methadone versus Buprenorphine
por: Kushnir, Alla, et al.
Publicado: (2023) -
Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?
por: Shah, Darshan, et al.
Publicado: (2016) -
Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan
por: Goshgarian, Gregory, et al.
Publicado: (2022) -
Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone
por: Gawronski, Kristen M, et al.
Publicado: (2014) -
Polygenic Risk Scores and the Need for Pharmacotherapy in Neonatal Abstinence Syndrome
por: Bibi, Shawana, et al.
Publicado: (2023)